Topics

Zimmer Biomet surpasses Q1 estimates, maintains short-term priorities

07:06 EDT 29 Apr 2019 | SmartBrief

Zimmer Biomet has beaten analyst expectations by generating $1.976 billion in net sales during the first quarter.  -More

Original Article: Zimmer Biomet surpasses Q1 estimates, maintains short-term priorities

NEXT ARTICLE

More From BioPortfolio on "Zimmer Biomet surpasses Q1 estimates, maintains short-term priorities"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...